Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma — Stella

Recruiting

Back to Newly Diagnosed Glioblastoma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Northwestern University, Chicago, Illinois

Key details

Phase

Safety & dosing

Sponsor

Northwestern University

Collaborators

Agenus Inc., CarThera

Enrollment target

~25 participants

Started

January 2024

Primary completion

May 2026

Age range

18 Years and older

Last updated October 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov